arrow
S

Stephan Polterauer

Medical University of Vienna
H指数:40
被引数:5,215

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Laparoscopic Lymph Node Assessment Prior to Open Radical Hysterectomy—A Two-Center Retrospective Study on Individualized Surgical Management of Early-Stage Cervical Cancer

腹腔镜淋巴结评估在开腹根治性子宫切除术前的应用——一项关于早期宫颈癌个体化手术管理的两中心回顾性研究

2026-09-160
OA
Cost-utility-analysis of molecular-integrated-profile for women with (high)intermediate risk endometrial cancer − PORTEC-4a an international, randomised, phase 3 trial
2026-01-300
PRE
Predictive value of BRCA1/RAD51C methylation in HGSOC – An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial

BRCA1/RAD51C甲基化在HGSOC中的预测价值——PAOLA-1/ENGOT-ov25 III期试验的附属研究

2025-06-030
PRE
Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial

Pembrolizumab或安慰剂联合放化疗,然后用Pembrolizumab或安慰剂治疗新诊断的高危局部晚期宫颈癌 (ENGOT-cx11/GOG-3047/KEYNOTE-A18): 一项随机,双盲,3期临床试验

2024-09-010
PRE
Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium
2024-05-061
OAAI
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

Pembrolizumab或安慰剂联合放化疗,然后用pembrolizumab或安慰剂治疗新诊断的高危局部晚期宫颈癌 (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): 一项随机,双盲,3期临床试验

LANCET
IF88.5
2024-04-0172
PRE
Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centres
2023-11-0126
OA
Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial

来自PAOLA-1/ENGOT-ov25试验的 ≥ 65岁卵巢癌患者维持奥拉帕尼和贝伐单抗的疗效和安全性

2023-03-0112
OAAI
Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)
CANCER
IF5.1
2022-06-1718
OAAI
Nomogram Predicting Overall Survival in Patients With Locally Advanced Cervical Cancer Treated With Radiochemotherapy Including Image-Guided Brachytherapy: A Retro-EMBRACE Study
2021-09-0130
PREAI